Lock Molecules

Lock Molecules

Beljanski discovered two plant extracts with anti-cancer activity: Pao  pereira and Rauwolfia vomitoria. The active molecules in the extracts, flavopereirine and alstonine,  bind specifically, or lock on, to the damaged DNA in cancer cells.  The lock molecules disrupt DNA duplication in cancer cells and as a result, the cancer cells are selectively removed from the body.  

 

Beljanski used the Oncotest, one of his most important scientific contributions, to discover the two anti-cancer extracts (1). In the Oncotest, DNA synthesis is set up in test tubes, so the amount of DNA made in different reactions can be compared.  Beljanski compared the total DNA synthesis from normal DNA templates to the total DNA synthesis from cancer DNA templates.  He found that the reactions with cancer DNA templates synthesized more DNA.  He reasoned that this is because the cancer DNA duplex is destabilized, having lost some of the hydrogen bonds that hold the duplex together. So the DNA polymerase works more efficiently and synthesizes more DNA from the destabilized and more accessible cancer DNA template (2). 

 

He understood that an extract that inhibited DNA synthesis from the cancer DNA template while having no effect on the reaction with normal cell DNA would represent an ideal anti-cancer agent. After testing many extracts, he found two, Pao pereira and Rauwolfia vomitoria, that behaved as ideal anti-cancers in the Oncotest.

 

The active compounds, flavopereirine and alstonine, were identified as lock molecules that target the structurally defective cancer DNA and inhibit DNA synthesis in cancer cells (3). Beljanski went on to show and subsequent research has confirmed that the extracts are effective in vivo, against human cancers.  The Oncotest also predicted that the lock molecules would be effective against a broad spectrum of cancers because DNA destabilization is a universal defect of cancer cells (4).  The mechanism revealed in the Oncotest is also at work in vivo: the extracts exert their anti-cancer effect by locking on to the destabilized DNA of cancer cells which initiates apoptosis or cell cycle arrest and selectively destroys cancer cells (5,6).

References

  1. Beljanski, M. “Oncotest: a DNA assay system for the screening of carcinogenic substances“. IRCS Medical science, 1979, 7, pp. 476.
  2. Beljanski, M. et al. “Differential susceptibility of cancer and normal DNA template allows the detection of carcinogens and anticancer drugs. Third NCI-EORTC Symposium on new drugs therapy.” Bordet Institute, Brussels, 1981.
  3. Beljanski, M. & Beljanski, M. S. ““Selective inhibition of in vitro synthesis of cancer DNA by alkaloids of the beta-carboline class.” Exp. Cell Biol, 1982;50(2):79.
  4. Beljanski, M., et al. “Correlation between in vitro DNA synthesis, DNA strand separation and in vivo multiplication of cancer cells.” Exp. Cell Biol., 1981;49(4):220-31.
  5. Bemis,  D., Capodice, J., Gorroochurn, P., Katz, A. and Buttyan. Anti-prostate cancer activity of a ß-carboline alkaloid enriched extract from Rauwolfia vomitoria. International Journal of Oncology. 29: 1065-1073, 2006. https://pubmed.ncbi.nlm.nih.gov/17016636/
  6. Bemis,  D., Capodice, J., Desai, M., Gorroochurn, P., Katz, A. and Buttyan. Beta-Carboline Alkaloid–Enriched Extract from the Amazonian Rain Forest Tree Pao Pereira Suppresses Prostate Cancer Cells. Journal of the Society for Integrative Oncology, Vol 7, No 2 (Spring), 2009: pp 59–65. https://www.researchgate.net/publication/26248012

Beljanski Approach for Different Stages of Cancer

Precancerous condition

Goal: Prevent the development of a tumor in individuals who are precancerous, with a high likelihood of developing a cancer without being diagnosed.

Characteristics of a precancerous condition:

Risk of cancer increases with age.  Other risk factors: presence of inflammatory condition such as benign prostatic hyperplasia which may progress to a tumor;  immediate family history of cancer;  presence of urinary disorders,  obesity, sedentary lifestyle, poor diet.

The Beljanski approach begins with a regimen to address obesity, along with a two month course of Pao pereira and Rauwolfia vomitoria extracts at appropriate dosage.

These extracts contain alkaloids of the beta-carboline class; alstonine (from Rauwolfia vomitoria, native to Africa) and flavopereirine (from Pao pereira, a tree that grows in South America) that react to the open sites of cancerous DNA and prevent genome duplication. Those extracts are known to induce death of precancerous cells and reduce inflammation, using different pathways (1,2,3).  

Also useful at this precancerous stage is the consumption of the green tea blend identified by Beljanski.  Recent studies have shown that this blend exerts a significant anti-cancer effect and the well- known anti-oxidant effects of green tea can help protect DNA from damage (4).

Localized cancerous condition (Stages 1 and 2)

Goal: Synergy of Beljanski approach with radiotherapy and chemotherapy, reduction of side effects and preservation of immunity.

Beljanski approach is used to complement Beljanski treatment consisting of taking extracts such as Pao pereira and Rauwolfia vomitoria, in suitable doses (5,6). They will work in synergy with other therapies to destroy cancer cells (7,8,9,10).

In addition, taking Beljanski’s Ginkgo biloba extract in conjunction with radiotherapy or brachytherapy will reduce the side effects of these treatments (11).  Ginkgo biloba is a tree that survived the destructive nuclear radiation in Japan.  The yellow leaf Ginkgo extract can protect tissues from radiation induced damage.  This extract helps reduce the side effects of radiotherapy (and brachytherapy), and prevent fibrosis caused by radiation.

Finally, in the event of a risk of low white blood cells or platelets counts due to chemotherapy, a sublingual intake of Beljanski’s RNA fragments, the day before each round of treatment enables the return of immunity, the regeneration of platelets and neutrophils, activation of Natural Killer cells and prevention of chromosomal breaks (12,13).  Beljanski’s RNA fragments are made from  a safe strain of E. coli K12 bacteria.  They facilitate proliferation of healthy white blood cells and platelets, replenishing the immune system.

Beljanski’s green tea blend  has broad spectrum anti-cancer activity and is recommended not only for cancer prevention but as part of the Beljanski approach to cancer treatment for potential suppression of tumor growth.

Advanced cancerous state (Stages 3 and 4)

Goal: Effectiveness of Beljanski extracts when chemotherapy is no longer effective.

The cancer is no longer localized, it has spread to surrounding and even distant organs including lungs, liver, lymph nodes and entered an advanced stage. Chemotherapy or hormone therapy treatments will be introduced into the bloodstream to reach the metastases.

At this stage, Beljanski treatment includes Pao pereira and Rauwolfia vomitoria extracts to attack cancer cells weakened by conventional treatments.  The active compounds in the extracts circulate in the blood,  and in the case of Pao pereira will even reach metastases in the brain (passing the meningeal barrier). The anti-cancer activity of the extracts are all the more effective when combined with conventional treatments—synergy of action. Yellow leaf Ginkgo biloba extract for its regulatory effect on globulins and enzymatic proteins, its protection of the genome and its reduction of the side effects of radiation therapies, brings comfort to patients in aggressive treatments.

For treatments seriously affecting the hematopoietic cells, and the essential immunity of the patient, taking RNA fragments before and during treatments will protect and restore immunity (platelets and white blood cells) without inducing proliferation of malignant cells. These sublingual doses should be taken before and during chemotherapy to avoid aplasia.

In some cases, after extended therapies, the tumor has metastasized,  has developed resistance to chemotherapy and continues to grow. Conventional therapies then have no solution to provide.  At this stage, Beljanski extracts still have the major advantage of being effective against hormone-resistant and chemo-resistant tumors (14,15,16).

Beljanski’s green tea is also important for patients with advanced cancers as part of a healthy lifestyle in which the consumption of food and beverage with anti-cancer effects provides support for the anti-cancer regimen.

References

  1. Liu J, Fang T, Li M, Song Y, Li J, Xue Z , Li J, Bu D, Liu W, Zeng Q, Zhang Y, Yun S, Huang R, Yan J. Pao Pereira extract attenuates testosterone-induced benign prostatic hyperplasia in rats by inhibiting 5α-reductase. Scientific Reports (2019) 9:19703. https://www.nature.com/articles/s41598-019-56145-z
  2. Dong Y,  Liu J, Xue Z, Sun J, Huang Z, Jing Y, Han B, Shen B, Yan J and Huang R.  Pao Pereira extract suppresses benign prostatic hyperplasia by inhibiting inflammation-associated NFκB signaling.  BMC Complementary Medicine and Therapies volume 20, Article number: 150 (2020). https://www.researchgate.net/publication/341439152
  3. Fang, T.,  Xue, Z., Li, J.,  Liu, J., Wu, D., Li, M., Song, Y.,  Yun, S. and Yan, J. Rauwolfia vomitoria extract suppresses benign prostatic hyperplasia by reducing androgen receptor and 5α-reductase expression in a rat model. Journal of Integrative Medicine. 2020 Dec 3: S2095-4964(20)30134-5. https://pubmed.ncbi.nlm.nih.gov/33341427/
  4. Ping Chen and Qi Chen, Effects of Different Tea Products on the Growth of Cancer Cells. EC Nutrition 14.12 (2019): 01-13. www.ecronicon.com/ecnu/pdf/ECNU-14-00734.pdf
  5. Bemis,  D., Capodice, J., Gorroochurn, P., Katz, A. and Buttyan. Anti-prostate cancer activity of a ß-carboline alkaloid enriched extract from Rauwolfia vomitoria. International Journal of Oncology. 29: 1065-1073, 2006. https://pubmed.ncbi.nlm.nih.gov/17016636/
  6. Bemis,  D., Capodice, J., Desai, M., Gorroochurn, P., Katz, A. and Buttyan. Beta-Carboline Alkaloid–Enriched Extract from the Amazonian Rain Forest Tree Pao Pereira Suppresses Prostate Cancer Cells. Journal of the Society for Integrative Oncology, Vol 7, No 2 (Spring), 2009: pp 59–65 https://www.researchgate.net/publication/26248012
  7. Yu, J. and Chen, Q. Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center.  “The Plant Extract of Pao Pereira Potentiates Carboplatin Effects Against Ovarian Cancer” Pharmaceutical Biology 2014 Jan; 52(1):36-43. https://www.researchgate.net/publication/256608022
  8. Yu, J, Ma, Y., Drisko, J., and Chen, Q. Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center.  “Antitumor Activities of Rauwolfia Vomitoria Extract and Potentiation of Carboplatin Effects Against Ovarian Cancer” Current Therapeutic Research, 75(2013)8-14. https://www.researchgate.net/publication/256691747
  9. Yu, J., Chen, Q., and Drisko, J. Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center. “Inhibition of Pancreatic Cancer and Potentiation of Gemcitabine Effects by the Extract of Pao Pereira” Oncology Reports 2013 Jul; 30(1):149-56. https://www.researchgate.net/publication/236837135
  10. Yu, J. and Chen, Q. Department of Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center. “Antitumor Activities of Rauwolfia Vomitoria and Potentiation of Gemcitabine Effects Against Pancreatic Cancer” Integr Cancer Ther 2014; 13:217-225. https://www.researchgate.net/publication/261882862
  11. Beljanski M, Cuasse JE, Nawrocki T, Beljanski M.  “Human Skin Fibrosis RNase Search for a Biological Inhibitor-Regulator“. Deutsche Zeitschrift für Onkologie, 26, 5, 1994, pp. 137-139. https://www.beljanski.org/beljanski-scientific-publications/127-human-skin-fibrosis-rnase-search-for-a-biological-inhibitor-regulator/
  12. Beljanski M, Plawecki M. Particular RNA fragments as promoters of leukocyte and platelet formation in rabbits.  Exp Cell Biol 1979;47(3):218-25. https://www.beljanski.org/beljanski-scientific-publications/83-particular-rna-fragments-as-promoters-of-leukocyte-and-platelet-formations-in-rabbits/
  13. Levin RD, Daehler M, Grutsch JF, Hall JL, Gupta D, Lis CG.   Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.  BMC Cancer. 2010 Oct 19;10:565. https://pubmed.ncbi.nlm.nih.gov/20955619/
  14. Chang C., Zhao W., Xie B., Deng Y., Han T., Cui Y., Dai Y., Zhang Z., Gao J., Guo H., Yan J. Pao pereira extract suppresses castration resistant prostate cancer cell growth, survival and invasion through inhibition of NFκB signaling. Integr. Cancer Ther. 2013 first published on November 27, 2013 as https://journals.sagepub.com/doi/full/10.1177/1534735413510557
  15. Dong, R., Chen, P., and Chen, Q. Extract of the medicinal plant Pao Pereira inhibits pancreatic cancer stem-like cells in vitro and in vivo. Integrative Cancer Therapies 2018 Dec;17(4):1204-1215 https://www.researchgate.net/publication/326286377
  16. Dong, R., Chen, P. and Chen, Q. Inhibition of pancreatic cancer stem cells by Rauwolfia vomitoria extract. Oncology Reports. Oncology Reports 2018 Dec;40(6):3144-3154. https://www.researchgate.net/publication/327731579

Quote Gretchen DuBeau

"The brilliant Mirko Beljanski, PhD, found miracles in nature—Pao pereira, a tree native to the Amazon, and Rauwolfia vomitoria, which is extracted from an African root bark—that proved to heal countless patients from cancer and AIDS. You would think these would be household names, and we would all be celebrating this major milestone in the war on cancer. But we aren’t. In fact, most people don’t know anything about these two natural remedies. 'WHY?'"

Gretchen DuBeau, Esq.

Executive Director : Alliance for Natural Health, USA


*Clinical trial with Beljanski’s RNA Fragments

Online magazine Bio Med Central BMC Cancer 10:565 – 2010.

Low platelet counts, a condition called Thrombocytopenia, is a side effect of chemo drugs that damage the bone marrow stem cells that normally produce platelets. The Phase I trial showed that Beljanski’s RNA fragments could prevent thrombocytopenia by inducing the production of new platelets. Patients taking the RNA fragments had their platelet levels return to normal and chemotherapy treatments were completed without dose reductions, platelet transfusions, or suspensions. The RNA fragments protected platelet levels in patients with many different types of cancer who were taking many different anti-cancer drugs. Moreover, patients did not suffer any negative side effects as a result of taking the RNA fragments. The results suggest further studies aimed at establishing the RNA fragments as a standard component in all chemotherapies that cause significant platelet loss.

CTCA - RNA Fragments In 2004, the Prestigious Cancer Treatment Centers of America® (CTCA) completed a clinical trial on the Beljanski’s formula of RNA fragments, which was conducted among cancer patients undergoing different chemotherapies. Thanks to the RNA fragments prepared according to Dr. Beljanski’s proprietary process, the cancer patients all recovered a stronger immune system and managed to go through the end of their chemotherapy treatment without getting thrombocytopenia – a frequent and dangerous side effect of the chemotherapy drugs.

Abstract

Background: Preclinical studies demonstrated that small chain RNA fragments accelerate the recovery of platelets numbers in animals exposed to high doses of chemotherapeutic drugs. There is anecdotal data supporting the same application in humans. The Phase I clinical trial described here was designed to investigate the relationship between the administration of small chain RNA fragments and the recovery in platelets following Chemotherapy Induced Thrombocytopenia (CIT).

Methods: Cancer patients with solid tumors that experienced post chemotherapy thrombocytopenia with a nadir of < = 80,000 platelets/ml were eligible for this clinical trial. There were no exclusions based on ECOG status, tumor type, tumor burden or chemotherapeutic agents. Patients received a unique preparation of RNA derived from either E. coli or yeast. Ten patients per group received 20, 40, or 60 mg as a starting dose. Subjects self administered RNA fragments sublingually on an every other day schedule while undergoing chemotherapy. The dose was escalated in 20 mg increments to a maximum dose of 80 mg if the nadir was < 80,000 platelets/ml at the start of the next cycle. Subjects were treated for three cycles of chemotherapy with the maximum effective dose of RNA fragments. Subjects continued on planned chemotherapy as indicated by tumor burden without RNA fragment support after the third cycle. Subjects kept a diary indicating RNA fragment and magnesium administration, and any experienced side effects.

Results: Patients receiving E. coli RNA fragments demonstrated a more rapid recovery in platelet count and higher nadir platelet count. None of the patients receiving the E. coli RNA fragments required a chemotherapy dose reduction due to thrombocytopenia. The optimal dose for minimizing CIT was 80 mg. Conversely, subjects receiving yeast RNA fragments with dose escalation to 80 mg required a chemotherapy dose reduction per American Society of Clinical Oncology guidelines for grade 3 and 4 thrombocytopenia.

Conclusions: Patients receiving myelosuppressive chemotherapy experienced an improvement in the platelet nadir and shorter recovery time when receiving concurrent E coli RNA fragments, when compared to patients who received yeast RNA fragments. These data indicate that 60 and 80 mg doses of E. coli RNA accelerated platelet recovery. Further clinical investigations are planned to quantify the clinical benefits of the E. coli RNA at the 80 mg dose in patients with chemotherapy induced thrombocytopenia.

Trial Registration: Clinical Trials.gov Identifier: NCT01163110

Click here to view publication.


Low platelet counts, a condition called thrombocytopenia, is a side effect of chemo drugs that damage the bone marrow stem cells that normally produce platelets. This Phase I trial showed that Beljanski’s RNA fragments could prevent thrombocytopenia by inducing the production of new platelets. Patients taking the RNA fragments had their platelet levels return to normal and chemotherapy treatments were completed without dose reductions, platelet transfusions, or suspensions. The RNA fragments protected platelet levels in patients with many different types of cancer who were taking many different anti-cancer drugs. Moreover, patients did not suffer any negative side effects as a result of taking the RNA fragments.